TORONTO, July 14, 2014 - Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, has announced a second closing of its recently announced Series B financing, bringing the total raised in this round to $25.5 million.
In conjunction with this closing, new investor BDC Capital joined as an investor and Dion Madsen, senior managing partner at BDC Capital, will join Xagenic's Board of Directors.
From our archives: MaRS Innovation's lead start-up completes $20 million ...
Dr. Andrew (Andy) Sinclair, OtoSim’s CEO, was interviewed by PharmaBoadroom.com on October 10, 2013 to discuss the company’s success and plans for the future.
OtoSim's otoscopy training device is revolutionizing the way medical students, teachers and nurses perfect otoscopy techniques. The invention, developed by Doctors Vito Forte and Paolo Campisi at the Hospital for Sick Children (SickKids), provides them with a device that simulates the structure of an actual ear rather than only reading techniques from a textbook.
The article highlights how effective ...
Technology developed by Dr. Stuart Berger at UHN is first project funded through partnership
TORONTO, Dec. 11, 2013 - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has announced the first project funded through the Pfizer Inc. and MaRS Innovation strategic partnership.
Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector, which is a rapid-growth area.
This announcement was covered by BetaKit.
His technology generates cell lines with improved protein production and survival properties, important in the ...
In a November 25 article in Biotechnology Focus magazine, author Shawn Lawrence highlights Stem Cell Therapeutics and Trillium Therapeutics Inc. coming together in a reverse merger that creates more opportunities to advance early-stage research.
The article profiles Dr. Aaron Schimmer and his discovery that Tigecycline is effective in killing leukemia cells and leukemia stem cells by shutting down their energy supply.
Here's a quote from Lawrence's article:
“Dr. Schimmer’s research is focused on drug repurposing – finding new indications for approved therapeutics. Focusing on established drugs ...
MaRS Innovation's (MI) Lyssa Neel, co-director of the UTEST program and project manager, has been selected to represent MI's ICT start-up companies at the TechWomen Canada program in San Francisco, which runs May 13 to 16, 2013.
The announcement was covered in TechVibes:
TechWomen Canada is run by the Canadian Consulate and is focused on providing Canadian women leaders in the ICT sector an opportunity to expand both professional and business networks in Silicon Valley. (more…)
Deal strengthens competitiveness of online learning platform for global mobile learners
WATERLOO, ON, Canada (April 23, 2013) — ClevrU Corporation today announced that it has acquired NewMindsets Inc., a company founded on online pedagogy researched and developed by two Schulich School of Business professors that has provided leading-edge educational content and services to over 10,000 Schulich students at York University over the past decade.
Through the acquisition, ClevrU will fully integrate NewMindsets’ proven e-teaching pedagogy in leadership, researched and developed by Professors ...
Happy New Year. Here's a snapshot of some spin-off stories you may have missed over the holiday break:
Flybits and Flybits Lite, the startup company's context-aware mobile technology that anyone can use, was mentioned in a Smithsonian.com article as one of six technologies changing the way the way humans live.
ApneaDx was featured in a company profile post on the MaRS Blog: "ApneaDx: First we take Ontario, then we take the world."
ScarX Therapeutics launched its website.
OtoSim Inc. co-founder Dr. Vito ...